GlassScriptPhysician profile
Melissa D Berg
NPI 1548700107
$2,386.76
in general payments reported to CMS, 2019-2025
24 companies · $155 in 2025
The $155 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $464 · 2022: $325 · 2023: $844 · 2024: $600 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,598.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $770.95 | 2021-2025 | |
| Myriad Women'S Health, INC. | $363.94 | 2023 | Myrisk |
| Astellas Pharma US INC | $168.93 | 2022-2024 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $137.96 | 2022-2025 | |
| Exeltis, USA INC. | $136.79 | 2021-2024 | Slynd |
| Biohaven Pharmaceuticals, INC. | $110.44 | 2021 | |
| Sumitomo Pharma America, INC. | $88.88 | 2023-2024 | Myfembree |
| Acella Pharmaceuticals, LLC | $74.64 | 2021-2025 | NP Thyroid 60 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.36 | 2021-2023 | Xifaxan |
| Gynesonics, INC. | $62.07 | 2023-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Biohaven Pharmaceutical Holding Company LTD. | $54.09 | 2022 | |
| Therapeuticsmd, INC. | $53.66 | 2021 | |
| Ibsa Pharma INC. | $43.11 | 2023-2024 | Tirosint, Licart, Tirosint |
| Coopersurgical, INC. | $37.58 | 2024-2025 | Paragard T 380a |
| Exact Sciences Corporation | $35.27 | 2023-2024 | Cologuard Collection Kit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $33.48 | 2022-2023 | Acessa Provu System |
| Lupin INC. | $29.54 | 2021 | |
| Avion Pharmaceuticals | $25.22 | 2021 | |
| Scynexis, INC. | $18.42 | 2022 | |
| Pfizer INC. | $18.28 | 2024 | |
| Allergan, INC. | $14.69 | 2022 | |
| Novo Nordisk INC | $13.52 | 2022 | |
| Minerva Surgical, INC | $13.05 | 2023 | |
| Mylan Pharmaceuticals INC. | $12.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Berg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.